SITE005-0150

SITE005 (FRA) › SITE005-0150

SITE005-0150

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2026-02-25

completed

AEs

6

Serious

1

Dropout signal

–

Adverse events

6

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-11-09 (study day 64); relationship: not assessed

mild assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-11-04 (study day 59); relationship: not assessed

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-10-13 (study day 37); relationship: NOT RELATED

moderate assessed

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-09-25 (study day 19); relationship: not assessed

moderate assessed

Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-09-17 (study day 11); relationship: NOT RELATED; serious criteria: hospitalization

severe serious assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-09-13 (study day 7); relationship: not assessed

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.